Clinical Trial Update: Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion [Phase 4]

View source ↗

Summary

Phase 4 trial investigating nateglinide's effect on postprandial glucose by restoring early-phase insulin secretion in type 2 diabetes; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Nateglinide (nateglinide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2012-10-19